The landscape of emerging biopharma companies is an extraordinarily dynamic space. There’s a constant barrage of significant news that can portend the next big medical innovation—but also obstacles that these new biotechs will have to face down. In this Emerging Biopharma newsletter, you’ll get a round-up of key headlines over the past quarter so you can stay on top of this fast-moving area.
| | By Ben Adams Welcome to this year's Fierce Biotech's Fierce 15. Join us in celebrating 2022's best of the best biotech startups. This year, we focused more than ever before on diversity in management and geography across the biotech world, highlighting a broader range of teams, leaders and science. |
|
|
| | This week on "The Top Line," we discuss Sarepta's phase 2 Duchenne muscular dystrophy clinical trial that was green-lit earlier this week after a clinical hold in June. We also chat the opposing results on either side of the pond for Illumina quest for Grail. |
|
|---|
|
